Sandoz acquires Astra Zeneca's generics subsidiary in Denmark
Sandoz, a Novartis company, has acquired Durascan, the generics subsidiary of Astra Zeneca in Denmark, for an undisclosed sum.
Sandoz, a Novartis company, has acquired Durascan, the generics subsidiary of Astra Zeneca in Denmark, for an undisclosed sum.
The transaction will make Sandoz the number two player in local generics market and provide an operational hub for entire Nordic region.
With net sales of €25m in 2003, Durascan has a broad portfolio of generic medicines that provide growth opportunities for Sandoz throughout the Nordic region. In addition, Durascan provides Sandoz with state-of-the-art quality assurance and logistics facilities.
'The acquisition of Durascan provides Sandoz with a leadership position in the Danish generics market and a platform to increase our presence in the Nordic region with its strong and highly competitive generics environment,' said Christian Seiwald, ceo of Sandoz. 'It is perfectly in line with our strategy to grow organically, while seeking selected regional or therapeutic acquisitions.'